Literature DB >> 16601869

Effect of docosahexaenoic acid administration on plasma lipid profile and metabolic parameters of children with methylmalonic acidaemia.

L Aldámiz-Echevarría1, P Sanjurjo, J Elorz, J A Prieto, C Pérez, F Andrade, J Rodríguez-Soriano.   

Abstract

AIM: To evaluate the effect of administration of docosahexaenoic acid (DHA) on dyslipidaemia, plasma fatty acid composition and metabolic parameters of children with isolated methylmalonic acidaemia (MMA) (McKusick 25100).
METHODS: Four children (3 male, 1 female) with MMA (mut(0)), participated in a crossover, randomized study of DHA administration (25 mg/kg per day, divided into three daily doses). The control group comprised 56 healthy children, aged 10+/- 2.7 years, (51 male, 5 female), who were followed in our clinic owing to possible familial risk of cardiovascular disease.
RESULTS: The comparison of plasma fatty acid composition of children with MMA versus control children demonstrated that the patients had significantly higher values for oleic acid (p = 0.004) and linolenic acid (p = 0.008). No differences were observed in the levels of DHA and arachidonic acid. Plasma concentrations of insulin, glycine, ammonia, total cholesterol and cholesterol fractions did not change with DHA administration. No significant changes were observed in urinary excretion of methylmalonic acid. As expected, the percentage of DHA and n-3 fatty acids in plasma increased significantly after therapy (p = 0.005 and 0.014, respectively). The most remarkable result was a decrease of plasma levels of triglycerides after DHA therapy (p = 0.014).
CONCLUSION: As previously found in normal children, dietary supplementation with DHA decreases the triglyceride levels, normalizing the hypertriglyceridaemia of these children without any evidence of short-term adverse effects.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16601869     DOI: 10.1007/s10545-006-0182-6

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  41 in total

1.  The n-of-1 randomized controlled trial: clinical usefulness. Our three-year experience.

Authors:  G H Guyatt; J L Keller; R Jaeschke; D Rosenbloom; J D Adachi; M T Newhouse
Journal:  Ann Intern Med       Date:  1990-02-15       Impact factor: 25.391

2.  Combined liver-kidney transplantation in methylmalonic acidemia.

Authors:  W G van 't Hoff; M Dixon; J Taylor; P Mistry; K Rolles; L Rees; J V Leonard
Journal:  J Pediatr       Date:  1998-06       Impact factor: 4.406

3.  Neurodegeneration in methylmalonic aciduria involves inhibition of complex II and the tricarboxylic acid cycle, and synergistically acting excitotoxicity.

Authors:  Jürgen G Okun; Friederike Hörster; Lilla M Farkas; Patrik Feyh; Angela Hinz; Sven Sauer; Georg F Hoffmann; Klaus Unsicker; Ertan Mayatepek; Stefan Kölker
Journal:  J Biol Chem       Date:  2002-02-14       Impact factor: 5.157

4.  Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge.

Authors:  W T Friedewald; R I Levy; D S Fredrickson
Journal:  Clin Chem       Date:  1972-06       Impact factor: 8.327

5.  Plasma selenium levels in treated phenylketonuric patients.

Authors:  A Rottoli; G Lista; G Zecchini; C Butté; R Longhi
Journal:  J Inherit Metab Dis       Date:  1985       Impact factor: 4.982

Review 6.  The management and outcome of propionic and methylmalonic acidaemia.

Authors:  J V Leonard
Journal:  J Inherit Metab Dis       Date:  1995       Impact factor: 4.982

7.  Long-term follow-up of 77 patients with isolated methylmalonic acidaemia.

Authors:  E R Baumgarter; C Viardot
Journal:  J Inherit Metab Dis       Date:  1995       Impact factor: 4.982

Review 8.  Omega-3 polyunsaturated fatty acid regulation of gene expression.

Authors:  P T Price; C M Nelson; S D Clarke
Journal:  Curr Opin Lipidol       Date:  2000-02       Impact factor: 4.776

9.  International Federation of Clinical Chemistry standardization project for measurements of apolipoproteins A-I and B. IV. Comparability of apolipoprotein B values by use of International Reference Material.

Authors:  S M Marcovina; J J Albers; H Kennedy; J V Mei; L O Henderson; W H Hannon
Journal:  Clin Chem       Date:  1994-04       Impact factor: 8.327

10.  Randomized controlled trial of the effect of n-3 fatty acid supplementation on the metabolism of apolipoprotein B-100 and chylomicron remnants in men with visceral obesity.

Authors:  Dick C Chan; Gerald F Watts; Trevor A Mori; P Hugh R Barrett; Trevor G Redgrave; Lawrence J Beilin
Journal:  Am J Clin Nutr       Date:  2003-02       Impact factor: 7.045

View more
  2 in total

Review 1.  Advances and challenges in the treatment of branched-chain amino/keto acid metabolic defects.

Authors:  Ina Knerr; Natalie Weinhold; Jerry Vockley; K Michael Gibson
Journal:  J Inherit Metab Dis       Date:  2011-02-03       Impact factor: 4.982

Review 2.  Long-chain polyunsaturated fatty acids in inborn errors of metabolism.

Authors:  Katalin Fekete; Tamás Decsi
Journal:  Nutrients       Date:  2010-09-15       Impact factor: 5.717

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.